AYTU BioPharma (AYTU) Stock: Buy, Sell, or Hold?
AYTU - AYTU BioPharma, Inc. Common Stock
$2.10
0.03 (1.45%)
▲
5d:
-3.23%
30d:
-8.1%
90d:
-6.67%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 12, 2026
Get Alerted When AYTU Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AYTU shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: AYTU shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: AYTU is currently trading at $2.10, which is considered slightly low relative to its 30-day fair value range of $2.05 to $2.26. From a valuation perspective, the stock is trading at a discount (Forward PE: -27.6) compared to its historical average (14.8). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AYTU is showing sideways momentum. The price is currently testing key support at $2.04. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AYTU scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $9.67 (+367.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AYTU is showing sideways momentum. The price is currently testing key support at $2.04. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AYTU scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $9.67 (+367.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.05 -
$2.26
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
95.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 367.0% below Wall St target ($9.67)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Bottoming setup, but lagging the sector by 15% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$2.05 -
$2.26
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.04
Resistance Level
$2.35
Current Trend
Sideways
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-27.60
Wall Street Target
$9.67
(+367.0%)
Revenue Growth (YoY)
6.4%
Profit Margin
-24.8%
PE vs Historical
-27.6 vs 14.8
CHEAP
Share & Embed Analysis
Last updated: October 05, 2026 12:47 PM ET
Data refreshes hourly during market hours. Next update: 1:47 PM
Data refreshes hourly during market hours. Next update: 1:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AYTU showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
28 analysts |
$208 | 57 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 65 BUY |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$57 | 61 BUY |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
AMLX
Amylyx Pharmaceuticals I… |
STRONG BUY
12 analysts |
$42 | 58 HOLD |
